KR101052816B1 - 화합물, 조성물 및 방법 - Google Patents

화합물, 조성물 및 방법 Download PDF

Info

Publication number
KR101052816B1
KR101052816B1 KR1020047016771A KR20047016771A KR101052816B1 KR 101052816 B1 KR101052816 B1 KR 101052816B1 KR 1020047016771 A KR1020047016771 A KR 1020047016771A KR 20047016771 A KR20047016771 A KR 20047016771A KR 101052816 B1 KR101052816 B1 KR 101052816B1
Authority
KR
South Korea
Prior art keywords
propyl
optionally substituted
methyl
delete delete
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020047016771A
Other languages
English (en)
Korean (ko)
Other versions
KR20050036908A (ko
Inventor
앤드류 맥도날드
구스타브 베르그네스
바이니안 펭
데이빗 제이 씨 주니어 모르간스
스티븐 데이빗 나이트
케네쓰 에이 뉴랜더
다쉬욘트 다낙
크리스토퍼 에쓰 브룩
Original Assignee
스미스 클라인 비참 코포레이션
싸이토키네틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스미스 클라인 비참 코포레이션, 싸이토키네틱스, 인코포레이티드 filed Critical 스미스 클라인 비참 코포레이션
Publication of KR20050036908A publication Critical patent/KR20050036908A/ko
Application granted granted Critical
Publication of KR101052816B1 publication Critical patent/KR101052816B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
KR1020047016771A 2002-04-17 2003-04-11 화합물, 조성물 및 방법 Expired - Fee Related KR101052816B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US37345402P 2002-04-17 2002-04-17
US60/373,454 2002-04-17
US41068202P 2002-09-13 2002-09-13
US60/410,682 2002-09-13
PCT/US2003/011432 WO2003088903A2 (en) 2002-04-17 2003-04-11 Compounds, compositions, and methods

Publications (2)

Publication Number Publication Date
KR20050036908A KR20050036908A (ko) 2005-04-20
KR101052816B1 true KR101052816B1 (ko) 2011-07-29

Family

ID=29254526

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047016771A Expired - Fee Related KR101052816B1 (ko) 2002-04-17 2003-04-11 화합물, 조성물 및 방법

Country Status (21)

Country Link
US (7) US6924376B2 (https=)
EP (1) EP1511734B1 (https=)
JP (1) JP4664597B2 (https=)
KR (1) KR101052816B1 (https=)
CN (1) CN100381437C (https=)
AR (1) AR039419A1 (https=)
AT (1) ATE471931T1 (https=)
AU (1) AU2003234733B2 (https=)
BR (1) BR0309278A (https=)
CA (1) CA2482041C (https=)
DE (1) DE60333094D1 (https=)
DK (1) DK1511734T3 (https=)
IL (2) IL164581A (https=)
MX (1) MXPA04010240A (https=)
MY (1) MY140169A (https=)
NO (1) NO330433B1 (https=)
NZ (1) NZ536190A (https=)
PL (1) PL211300B1 (https=)
RU (1) RU2308454C9 (https=)
TW (1) TWI282337B (https=)
WO (1) WO2003088903A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ536190A (en) * 2002-04-17 2007-08-31 Cytokinetics Inc Compounds for treating cellular proliferative diseases by modulating the activity of the mitotic kinesin KSP
DE60326248D1 (de) * 2002-07-17 2009-04-02 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
EP1554265A4 (en) * 2002-09-13 2008-05-07 Cytokinetics Inc COMPOSITIONS, COMPOSITIONS AND M THODES
AR050920A1 (es) * 2003-03-07 2006-12-06 Astrazeneca Ab Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos
NZ542227A (en) * 2003-03-07 2008-12-24 Astrazeneca Ab Novel fused heterocycles and uses thereof
US20050165089A1 (en) * 2003-10-06 2005-07-28 Gustave Bergnes Compounds, compositions and methods
WO2005087747A1 (en) * 2004-03-08 2005-09-22 Wyeth Ion channel modulators
US20070191448A1 (en) * 2004-03-08 2007-08-16 Robert Zelle Ion channel modulators
ES2311992T3 (es) * 2004-05-21 2009-02-16 Novartis Vaccines And Diagnostics, Inc. Derivados de quinolina sustituida com,o inhibidores de cinesina mitotica.
WO2006008523A1 (en) * 2004-07-22 2006-01-26 Astrazeneca Ab Fused pyrimidones usefuel in the treatment and the prevention of cancer
KR20070046175A (ko) * 2004-08-18 2007-05-02 아스트라제네카 아베 선택된 융합 복소환 및 이의 용도
US20060041128A1 (en) * 2004-08-18 2006-02-23 Astrazeneca Ab Selected fused heterocyclics and uses thereof
EP1781674A1 (en) 2004-08-18 2007-05-09 AstraZeneca AB Enantiomers of selected fused pyrimidones and uses in the treatment and prevention of cancer
WO2006060737A2 (en) * 2004-12-03 2006-06-08 Takeda San Diego, Inc. Mitotic kinesin inhibitors
US20090221488A1 (en) * 2005-12-08 2009-09-03 Wood Kenneth W Certain Compositions and Methods of Treatment
WO2007106818A1 (en) * 2006-03-13 2007-09-20 University Of Florida Research Foundation, Inc. Synthesis of pentafluorosulfanyl (sf5)-substituted heterocycles and alkynes
WO2007134183A2 (en) * 2006-05-13 2007-11-22 Advanced Technology Materials, Inc. Chemical reagent delivery system utilizing ionic liquid storage medium
WO2008086122A2 (en) 2007-01-05 2008-07-17 Novartis Ag Imidazole derivatives as kinesin spindle protein inhibitors (eg-5)
NZ599830A (en) 2009-11-05 2014-08-29 Rhizen Pharmaceuticals Sa Novel kinase modulators
KR102263079B1 (ko) * 2009-11-05 2021-06-10 리젠 파마슈티컬스 소시에떼 아노님 신규한 벤조피란 키나제 조절제
WO2012066330A1 (en) 2010-11-17 2012-05-24 Heptares Therapeutics Limited Compounds useful as a2a receptor inhibitors
PH12013502240B1 (en) * 2011-05-04 2018-06-27 Rhizen Pharmaceuticals Sa Novel compounds as modulators of protein kinase
RS56494B1 (sr) * 2012-07-04 2018-01-31 Rhizen Pharmaceuticals S A Selektivni inhibitori pi3k delta
KR20150095779A (ko) * 2012-12-13 2015-08-21 글락소스미스클라인 엘엘씨 제스트 인핸서 상동체 2 억제제
AU2014288839B2 (en) 2013-07-10 2017-02-02 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of Zeste Homolog 2 inhibitors
EP3325462A4 (en) * 2015-07-23 2019-06-19 Pharmakea, Inc. INHIBITORS OF LYSYL OXIDASE-LIKE 2 AND USES OF SAID INHIBITORS
CA3013917A1 (en) 2016-02-09 2017-08-17 Pharmakea, Inc. Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof
CN111991389B (zh) * 2020-09-17 2021-11-23 陕西科技大学 Sb-743921用于制备抗真菌药物的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037871A1 (en) 2001-11-01 2003-05-08 Astrazeneca Ab Therapeutic quinolone compounds with 5-ht-antagonistic properties

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US169159A (en) * 1875-10-26 Improvement in corsets
US116400A (en) * 1871-06-27 Improvement in heels for boots and shoes
US55054A (en) * 1866-05-29 Improvement in lamp-chimneys
GB728767A (en) * 1951-10-12 1955-04-27 Wander Ag Dr A 2-substituted chromone compounds, and a method of making same
NL84159C (https=) 1952-06-30
EP0020018B1 (en) 1979-05-19 1983-06-01 Beecham Group Plc Chroman derivatives, processes for their preparation and pharmaceutical compositions containing them
DE3177130D1 (de) 1980-08-30 1990-01-11 Hoechst Ag Aminosaeurederivate, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung.
US4434295A (en) 1982-05-17 1984-02-28 The Upjohn Company Anti-atherosclerotic 6,7-dihydro-7,7-disubstituted-khellin analogs
US4434296A (en) 1982-05-17 1984-02-28 The Upjohn Company Process for preparing intermediates for antiatherosclerotic compounds
US4459420A (en) 1982-05-17 1984-07-10 The Upjohn Company Pyrogallol synthesis of anti-atherogenic furochromones
US4482558A (en) 1982-06-18 1984-11-13 Pfizer Inc. Antifungal amide and urea derivatives of (3-amino-2-aryl-2-hydroxyprop-1-yl)-1H-1,2,4-triazoles
JPS62201882A (ja) * 1985-11-18 1987-09-05 Yamanouchi Pharmaceut Co Ltd イソフラボン誘導体
IN164232B (https=) 1986-04-11 1989-02-04 Hoechst India
IL85554A0 (en) 1987-03-02 1988-08-31 Takeda Chemical Industries Ltd Chromone derivatives
JPH0753725B2 (ja) 1987-10-08 1995-06-07 富山化学工業株式会社 ４ｈ―１―ベンゾピラン―４―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
MX13485A (es) * 1987-10-19 1993-05-01 Pfizer Procedimiento para obtener tetralinas, cromados y compuestos relacionados, sustituidos
USH1427H (en) 1988-04-06 1995-04-04 Briet; Phillipe Substituted flavonoid compounds, their salts, their manufacture and their use in combination with interleukin-2
IL89840A (en) 1988-04-06 1996-10-31 Lipha Substituted flavonoid compounds and salts thereof their preparation and pharmaceutical composition containing them
US5304548A (en) 1988-08-16 1994-04-19 The Upjohn Company Bivalent ligands effective for blocking ACAT enzyme for lowering plasma triglycerides and for elevating HDL cholesterol
US5180717A (en) 1988-08-16 1993-01-19 The Upjohn Company Bivalent ligands effective for blocking ACAT enzyme for lowering plasma triglycerides and for elevating HDL cholesterol
US5284856A (en) 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
DE3836676A1 (de) 1988-10-28 1990-05-03 Hoechst Ag Die verwendung von 4h-1-benzopyran-4-on-derivaten, neue 4h-1-benzopyran-4-on-derivate und diese enthaltende arzneimittel
AU634994B2 (en) * 1988-12-21 1993-03-11 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
US5703075A (en) 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
US4977162A (en) 1989-07-13 1990-12-11 Rorer Pharmaceutical Corporation Quinolinyl-chromone derivatives and use for treatment of hypersensitive ailments
US5082849A (en) 1989-07-13 1992-01-21 Huang Fu Chich Quinolinyl-benzopyran derivatives as antagonists of leukotriene D4
US5032598A (en) 1989-12-08 1991-07-16 Merck & Co., Inc. Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents
US5215989A (en) 1989-12-08 1993-06-01 Merck & Co., Inc. Nitrogen-containing heterocyclic compounds as class III antiarrhythmic agents
EP0525123B1 (en) 1990-06-20 1997-09-17 PHARMACIA & UPJOHN COMPANY Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
ATE161837T1 (de) 1990-07-25 1998-01-15 Teijin Ltd Benzopyran derivat, seine darstellung und pharmazeutische zusammensetzung, welche dieses enthält
CA2067167A1 (en) 1990-09-28 1992-03-29 Tokuo Matuzaki Method of producing carbonic acid diester
AU8506791A (en) 1990-10-01 1992-04-28 Janssen Pharmaceutica N.V. Novel 4-piperidinylcarbonyl derivatives
JPH05301813A (ja) 1991-10-15 1993-11-16 Kao Corp 皮膚外用剤
EP0623608B1 (en) 1992-01-24 2001-05-30 Teijin Limited Benzopyran derivative, production thereof, and pharmaceutical preparation containing the same as active ingredient
GB9203497D0 (en) * 1992-02-19 1992-04-08 Lilly Industries Ltd Pharmaceutical compounds
US5605896A (en) 1992-02-25 1997-02-25 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 adrenergic and 5HT1A activities
FR2693196B1 (fr) 1992-07-03 1994-12-23 Lipha Dérivés de benzopyranone ou de benzothiopyranone, procédé de préparation et composition pharmaceutique les contenant.
JP2579303Y2 (ja) * 1992-08-14 1998-08-27 株式会社共立 バリカン形刈払機
JPH09509428A (ja) 1994-02-23 1997-09-22 カイロン コーポレイション 薬理学的に活性な薬剤の血清半減期を増加させるための方法および組成物
WO1995034547A1 (en) * 1994-06-10 1995-12-21 Smithkline Beecham Plc C-4 amide substituted compounds and their use as therapeutic agents
US5607928A (en) 1994-08-05 1997-03-04 Zeneca Limited Carbapenem derivatives containing a bicyclic ketone substituent and their use as anti-infectives
GB9417969D0 (en) 1994-09-07 1994-10-26 King S College London Alkaloids and derivatives thereof
US5602171A (en) 1995-06-07 1997-02-11 Sugen Inc. Methods of inhibiting phosphatase activity and treatment of disorders associated therewith using naphthopyrones and derivatives thereof
AU4153496A (en) 1995-10-20 1997-05-07 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
NL1003520C2 (nl) 1996-07-05 1998-01-07 Stork Amsterdam Sterilisatie-inrichting en werkwijze voor het steriliseren van voorwerpen.
US5908934A (en) 1996-09-26 1999-06-01 Bristol-Myers Squibb Company Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs
JPH10273467A (ja) * 1997-01-29 1998-10-13 Snow Brand Milk Prod Co Ltd 新規テトラロン又はベンゾピラノン誘導体及びその製造方法
GB9807779D0 (en) 1998-04-09 1998-06-10 Ciba Geigy Ag Organic compounds
DE19850131A1 (de) * 1998-10-30 2000-05-04 Merck Patent Gmbh Chromenon- und Chromanonderivate
US6028088A (en) 1998-10-30 2000-02-22 The University Of Mississippi Flavonoid derivatives
US6087385A (en) 1998-10-30 2000-07-11 University Of Mississippi Flavonoid derivatives
DE19858341A1 (de) * 1998-12-17 2000-06-21 Merck Patent Gmbh Chromanderivate
US6399633B1 (en) * 1999-02-01 2002-06-04 Aventis Pharmaceuticals Inc. Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
GB9911071D0 (en) 1999-05-12 1999-07-14 Darwin Discovery Ltd Hydroxamic and carboxylic acid derivatives
WO2001016114A2 (en) 1999-08-27 2001-03-08 Chemocentryx, Inc. Heterocyclic compounds and methods for modulating cxcr3 function
GB9920912D0 (en) 1999-09-03 1999-11-10 Indena Spa Novel derivatives of flavones,xanthones and coumarins
GB9920910D0 (en) 1999-09-03 1999-11-10 Indena Spa Novel chalcones
JP4994552B2 (ja) 1999-09-16 2012-08-08 キュリス，インコーポレイテッド ヘッジホッグシグナル伝達経路のメディエーター、組成物及びそれらと関連する利用
US6552016B1 (en) 1999-10-14 2003-04-22 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6683192B2 (en) 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
EP1280789A1 (en) * 2000-05-03 2003-02-05 LG Life Sciences Ltd. Cdk inhibitors having 3-hydroxychromen-4-one structure
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
DE10036003A1 (de) 2000-07-25 2002-02-14 Aventis Cropscience Gmbh Herbizide Mittel
US6903121B1 (en) 2000-08-17 2005-06-07 Allergan, Inc. Treatment of tumors with acetylenes disubstituted with a phenyl or heteroaromatic group and a substituted chromanyl, thiochromanyl or tetrahydroquinolinyl group in combination with other anti-tumor agents
NZ526622A (en) 2000-12-11 2006-07-28 Amgen Sf Llc CXCR3 antagonists
JP2002322169A (ja) 2001-02-21 2002-11-08 Sankyo Co Ltd クロメン誘導体
BR0211513A (pt) 2001-07-27 2005-08-30 Curis Inc Mediadores de caminhos sinalizantes de hedgehog, composições e usos relacionados ao mesmo
JP2005511581A (ja) 2001-11-07 2005-04-28 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害剤
CA2467722A1 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Thienopyrimidinone derivatives as mitotic kinesin inhibitors
CA2468156A1 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Azolopyrimidinone compounds and their use
JP2005515208A (ja) 2001-12-06 2005-05-26 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂性キネシン阻害剤
WO2003049527A2 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
US20050107404A1 (en) 2001-12-06 2005-05-19 Fraley Mark E. Mitotic kinesin inhibitors
AU2003249597B2 (en) 2002-03-08 2007-06-28 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
NZ536190A (en) * 2002-04-17 2007-08-31 Cytokinetics Inc Compounds for treating cellular proliferative diseases by modulating the activity of the mitotic kinesin KSP
EP1509507A4 (en) 2002-05-23 2006-09-13 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
ATE356804T1 (de) 2002-06-14 2007-04-15 Merck & Co Inc Inhibitoren von mitotischem kinesin
EP1515724B1 (en) 2002-06-14 2009-10-21 Merck & Co., Inc. Mitotic kinesin inhibitors
AU2003247891A1 (en) 2002-07-08 2004-01-23 Merck & Co., Inc. Mitotic kinesin binding site
DE60326248D1 (de) * 2002-07-17 2009-04-02 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
WO2004014388A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors
EP1554265A4 (en) * 2002-09-13 2008-05-07 Cytokinetics Inc COMPOSITIONS, COMPOSITIONS AND M THODES
US20050165089A1 (en) * 2003-10-06 2005-07-28 Gustave Bergnes Compounds, compositions and methods
WO2005040163A1 (en) 2003-10-28 2005-05-06 Dr. Reddy's Laboratories Ltd Heterocyclic compounds that block the effects of advanced glycation end products (age)
JP4502322B2 (ja) 2004-11-08 2010-07-14 Ａｇｃテクノグラス株式会社 ガラス管の曲げ加工方法およびその成形用金型

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037871A1 (en) 2001-11-01 2003-05-08 Astrazeneca Ab Therapeutic quinolone compounds with 5-ht-antagonistic properties

Also Published As

Publication number Publication date
EP1511734A2 (en) 2005-03-09
US20120209012A1 (en) 2012-08-16
KR20050036908A (ko) 2005-04-20
NZ536190A (en) 2007-08-31
BR0309278A (pt) 2005-04-26
MXPA04010240A (es) 2005-06-08
PL373577A1 (en) 2005-09-05
CN100381437C (zh) 2008-04-16
AU2003234733B2 (en) 2009-01-29
NO330433B1 (no) 2011-04-11
US8633236B2 (en) 2014-01-21
RU2308454C9 (ru) 2008-05-10
US8329928B2 (en) 2012-12-11
DE60333094D1 (de) 2010-08-05
US7491746B2 (en) 2009-02-17
US8119678B2 (en) 2012-02-21
MY140169A (en) 2009-11-30
US20110230550A1 (en) 2011-09-22
HK1070656A1 (en) 2005-06-24
US7919524B2 (en) 2011-04-05
US20130053436A1 (en) 2013-02-28
DK1511734T3 (da) 2010-08-02
IL164581A (en) 2009-11-18
CA2482041A1 (en) 2003-10-30
JP2005523312A (ja) 2005-08-04
US20090005580A1 (en) 2009-01-01
US6924376B2 (en) 2005-08-02
PL211300B1 (pl) 2012-05-31
EP1511734A4 (en) 2006-05-10
NO20044662L (no) 2005-01-14
AR039419A1 (es) 2005-02-16
JP4664597B2 (ja) 2011-04-06
RU2004133325A (ru) 2005-10-27
EP1511734B1 (en) 2010-06-23
IL188954A (en) 2011-02-28
US7629477B2 (en) 2009-12-08
IL164581A0 (en) 2005-12-18
AU2003234733A1 (en) 2003-11-03
US20100105767A1 (en) 2010-04-29
CN1662508A (zh) 2005-08-31
CA2482041C (en) 2012-06-05
US20040082638A1 (en) 2004-04-29
RU2308454C2 (ru) 2007-10-20
ATE471931T1 (de) 2010-07-15
WO2003088903A2 (en) 2003-10-30
TW200408634A (en) 2004-06-01
TWI282337B (en) 2007-06-11
WO2003088903A3 (en) 2004-09-30
US20060020008A1 (en) 2006-01-26

Similar Documents

Publication Publication Date Title
KR101052816B1 (ko) 화합물, 조성물 및 방법
KR20050036911A (ko) 화합물들, 방법 및 조성물
WO2003106426A1 (en) Compounds, compositions, and methods
WO2004006865A2 (en) Compounds, compositions, and methods
KR20050075356A (ko) 화합물, 조성물 및 방법
EP1670456A2 (en) Compounds, compositions and methods
JP2007500213A (ja) 化合物、組成物および方法
EP1682534A2 (en) Pyrimidin-4-one compounds, compositions, and methods
JP2007500746A (ja) 化合物、組成物および方法
ES2348474T3 (es) Compuestos, composiciones y métodos.
HK1070656B (en) Compounds, compositions, and methods
JP2006526017A (ja) 化合物、組成物および方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20140726

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20140726

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000